Clinical Trial Update: Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity [Phase 3]

View source ↗

Summary

Phase 3 study evaluating daily oral semaglutide (Rybelsus) in East Asian adults who are overweight or living with obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Rybelsus (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Overweight and Obesity | Phase 3 | Status: COMPLETED